Unternehmen wird geladen
Just reported
Q4 FY2026 results
From Cencora's results release of 4. November 2026. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Revenue
Actual
88,35B $
+5,5 % y/y
+4,2 % q/qGuided
—
No guide given
EPS, GAAP
Actual
2,71 $
-31 % q/q
Guided
—
No guide given
Operating income, GAAP
Actual
906,8M $
-19 % q/q
Guided
—
No guide given
Company outlook
Full year 2027
- EPS, adjusted19,40 $ – 19,75 $First given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Cencora is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Distribution
Graded A or B and worth $2B or more: A first, then the largest.
All 11 graded companies in its industry
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21. Okt. 2026CBGraded C, now B
MCKMckesson Corporation4. Nov. 2026BAGraded B, now A
CVSCVS Health Corp4. Nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4. Nov. 2026BAGraded B, now A
BIIBBiogen Inc.28. Okt. 2026BAGraded B, now A
Gebaut aus den eigenen Einreichungen von Cencora, Inc. bei der US-Börsenaufsicht Securities and Exchange Commission (SEC). Die Zahlen sind wie berichtet, die Historie je Aktie auf die heutige Aktienbasis umgerechnet. Dies beschreibt ein Unternehmen — es ist keine Anlageberatung und keine Kauf- oder Verkaufsempfehlung.
